TOLERABILITY AND EFFICACY OF OLANZAPINE LONG ACTING INJECTION INSCHIZOPHRENIA â??A RANDOMIZED HOSPITAL BASED STUDY

Dr Varun S Mehta0 个研究点目标入组 40 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1. Diagnosis of Schizophrenia according to Diagnostic Criteria for Research of International Classification of Diseases -tenth edition (ICD-10)
•2. Documented reduction of 50 % from the baseline score in PANSS & BPRS within 4 weeks of treatment with oral olanzapine
•3. Patients with illness duration of >2 years
•4. Patients who had at least one relapse in previous one year due to non-adherence
•5. Patients who are anti-psychotic drug-free for last 4 weeks (oral) or 8 weeks (depot preparation)
•6. Patients who give written informed consent.

•1. Past history of documented non-response to Olanzapine
•2. Past history of use of olanzapine Long-Acting Injection
•3. History of significant head injury or epilepsy
•4.Any comorbid psychiatric illness or substance use in dependence pattern except nicotine or caffeine
•5.Known case of Hypertension, Diabetes mellitus or Dyslipidemia
•6. Body mass index greater than or equal to 30 kg/m2
•7.Not willing to give consent

发起方

Dr Varun S Mehta